(ADPT) Adaptive Biotechnologies - Ratings and Ratios
DNA Testing, Immunology Assays, Diagnostic Kits Laboratory
ADPT EPS (Earnings per Share)
ADPT Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 81.4% |
| Value at Risk 5%th | 114% |
| Reward | |
|---|---|
| Sharpe Ratio | 1.48 |
| Alpha Jensen | 127.55 |
| Character | |
|---|---|
| Hurst Exponent | 0.543 |
| Beta | 2.219 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.90% |
| Mean DD | 34.23% |
Description: ADPT Adaptive Biotechnologies August 13, 2025
Adaptive Biotechnologies Corp (NASDAQ:ADPT) is a life sciences company focused on providing innovative solutions for the diagnosis and treatment of various diseases. As a player in the Life Sciences Tools & Services sub-industry, the companys performance is closely tied to advancements in genomics, immunology, and biotechnology.
The stock has demonstrated significant price movement, with a current price of $12.15 and a 52-week range of $4.00 to $12.54. The short-term and long-term moving averages (SMA20: $10.92, SMA50: $10.90, SMA200: $8.13) indicate a positive trend, suggesting the stock is gaining momentum. The Average True Range (ATR) of 0.54, representing 4.44% of the current price, implies moderate volatility.
From a fundamental perspective, Adaptive Biotechnologies has a market capitalization of $1.857 billion, indicating a mid-cap status. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, is due to the companys negative earnings. The Return on Equity (RoE) stands at -60.87%, highlighting the companys current unprofitability. Key drivers for the companys valuation include revenue growth, particularly from its collaborations and commercialization of its immuno-sequencing technology, as well as progress in its clinical trials and partnerships.
To assess the companys potential, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating expense management will be crucial. Additionally, the companys cash burn rate and the time to profitability are essential metrics to monitor. The overall life sciences market trends, regulatory environment, and the competitive landscape will also impact ADPTs stock performance.
In evaluating Adaptive Biotechnologies, its essential to consider the broader context of the life sciences industry, including trends in precision medicine, the adoption of next-generation sequencing technologies, and the competitive positioning of the company within its sub-industry. The companys ability to innovate, form strategic partnerships, and navigate regulatory hurdles will be critical to its long-term success.
ADPT Stock Overview
| Market Cap in USD | 2,258m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2019-06-27 |
| Return 12m vs S&P 500 | 93.9% |
| Analyst Rating | 4.25 of 5 |
ADPT Dividends
Currently no dividends paidADPT Growth Ratios
| CAGR | 17.09% |
| CAGR/Max DD Calmar Ratio | 0.22 |
| CAGR/Mean DD Pain Ratio | 0.50 |
| Current Volume | 1613.3k |
| Average Volume | 1613.3k |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-79.6m TTM) > 0 and > 6% of Revenue (6% = 15.2m TTM) |
| FCFTA -0.13 (>2.0%) and ΔFCFTA 7.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 78.37% (prev 124.5%; Δ -46.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.12 (>3.0%) and CFO -60.5m > Net Income -79.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (163.2m) change vs 12m ago 10.61% (target <= -2.0% for YES) |
| Gross Margin 71.84% (prev 58.46%; Δ 13.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.18% (prev 31.74%; Δ 16.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.32 (EBITDA TTM -63.8m / Interest Expense TTM 11.8m) >= 6 (WARN >= 3) |
Altman Z'' -12.37
| (A) 0.40 = (Total Current Assets 281.4m - Total Current Liabilities 83.4m) / Total Assets 490.6m |
| (B) -2.75 = Retained Earnings (Balance) -1.35b / Total Assets 490.6m |
| warn (B) unusual magnitude: -2.75 — check mapping/units |
| (C) -0.16 = EBIT TTM -86.2m / Avg Total Assets 524.6m |
| (D) -4.71 = Book Value of Equity -1.35b / Total Liabilities 286.4m |
| Total Rating: -12.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.37
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -2.96% = -1.48 |
| 3. FCF Margin -24.90% = -7.50 |
| 4. Debt/Equity 0.40 = 2.42 |
| 5. Debt/Ebitda -0.42 = -2.50 |
| 6. ROIC - WACC (= -49.44)% = -12.50 |
| 7. RoE -40.97% = -2.50 |
| 8. Rev. Trend 59.47% = 4.46 |
| 9. EPS Trend 79.33% = 3.97 |
What is the price of ADPT shares?
Over the past week, the price has changed by -14.13%, over one month by -6.26%, over three months by +19.59% and over the past year by +123.88%.
Is Adaptive Biotechnologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ADPT is around 13.68 USD . This means that ADPT is currently overvalued and has a potential downside of -5.85%.
Is ADPT a buy, sell or hold?
- Strong Buy: 3
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ADPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.9 | 22.9% |
| Analysts Target Price | 17.9 | 22.9% |
| ValueRay Target Price | 16 | 9.9% |
ADPT Fundamental Data Overview November 11, 2025
P/S = 8.9333
P/B = 12.0655
Beta = 2.219
Revenue TTM = 252.8m USD
EBIT TTM = -86.2m USD
EBITDA TTM = -63.8m USD
Long Term Debt = 89.4m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 9.44m USD (from shortTermDebt, last quarter)
Debt = 81.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 26.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.13b USD (2.26b + Debt 81.8m - CCE 212.8m)
Interest Coverage Ratio = -7.32 (Ebit TTM -86.2m / Interest Expense TTM 11.8m)
FCF Yield = -2.96% (FCF TTM -62.9m / Enterprise Value 2.13b)
FCF Margin = -24.90% (FCF TTM -62.9m / Revenue TTM 252.8m)
Net Margin = -31.50% (Net Income TTM -79.6m / Revenue TTM 252.8m)
Gross Margin = 71.84% ((Revenue TTM 252.8m - Cost of Revenue TTM 71.2m) / Revenue TTM)
Gross Margin QoQ = 80.68% (prev 69.43%)
Tobins Q-Ratio = 4.34 (Enterprise Value 2.13b / Total Assets 490.6m)
Interest Expense / Debt = 3.63% (Interest Expense 2.97m / Debt 81.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -68.1m (EBIT -86.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.38 (Total Current Assets 281.4m / Total Current Liabilities 83.4m)
Debt / Equity = 0.40 (Debt 81.8m / totalStockholderEquity, last quarter 204.4m)
Debt / EBITDA = -0.42 (negative EBITDA) (Net Debt 26.8m / EBITDA -63.8m)
Debt / FCF = -0.43 (negative FCF - burning cash) (Net Debt 26.8m / FCF TTM -62.9m)
Total Stockholder Equity = 194.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.23% (Net Income -79.6m / Total Assets 490.6m)
RoE = -40.97% (Net Income TTM -79.6m / Total Stockholder Equity 194.3m)
RoCE = -30.37% (EBIT -86.2m / Capital Employed (Equity 194.3m + L.T.Debt 89.4m))
RoIC = -35.65% (negative operating profit) (NOPAT -68.1m / Invested Capital 190.9m)
WACC = 13.79% (E(2.26b)/V(2.34b) * Re(14.19%) + D(81.8m)/V(2.34b) * Rd(3.63%) * (1-Tc(0.21)))
Discount Rate = 14.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.11%
Fair Price DCF = unknown (Cash Flow -62.9m)
EPS Correlation: 79.33 | EPS CAGR: 54.06% | SUE: 4.0 | # QB: 3
Revenue Correlation: 59.47 | Revenue CAGR: 21.35% | SUE: 4.0 | # QB: 3
Additional Sources for ADPT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle